Znomics is employing breakthrough genetic advances with zebrafish to improve and speed human drug discovery. The Znomics discovery platform is based on two key technologies: 1) development of disease models and assays in zebrafish that are suitable for high-throughput in vivo drug discovery and 2) for drug target discovery, a new retroviral insertional mutagenesis system that allows for mutation of all of the 40,000+ zebrafish genes followed by rapid recovery of genes of interest. This tagged mutant gene library ('ZeneMark™ Library') will be the first of its kind in any vertebrate. With this set of lesions, company scientists can then identify all genes that contribute to a particular disease-related process.